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Background: The nuclear factor-κB (NF-κB) proteins are a small group of heterodimeric transcription factors that
play an important role in regulating the inflammatory, immune, and apoptotic responses. NF-κB activity is
suppressed by association with the inhibitor IκB. Aberrant NF-κB signaling activity has been associated with the
development of cancer, chronic inflammatory diseases and auto-immune diseases. The IKK protein complex is
comprised of IKKα, IKKβ and NEMO subunits, with IKKβ thought to play the dominant role in modulating NF-κB
activity. Therefore, the discovery of new IKKβ inhibitors may offer new therapeutic options for the treatment of
cancer and inflammatory diseases.
Results: A structure-based molecular docking approach has been employed to discover novel IKKβ inhibitors from
a natural product library of over 90,000 compounds. Preliminary screening of the 12 highest-scoring compounds
using a luciferase reporter assay identified 4 promising candidates for further biological study. Among these, the
benzoic acid derivative (1) showed the most promising activity at inhibiting IKKβ phosphorylation and TNF-α-
induced NF-κB signaling in vitro.
Conclusions: In this study, we have successfully identified a benzoic acid derivative (1) as a novel IKKβ inhibitor via
high-throughput molecular docking. Compound 1 was able to inhibit IKKβ phosphorylation activity in vitro, and
block IκBα protein degradation and subsequent NF-κB activation in human cells. Further in silico optimization of the
compound is currently being conducted in order to generate more potent analogues for biological tests.Background
The nuclear factor-κB (NF-κB) proteins are a small
group of heterodimeric transcription factors that play
an important role in regulating inflammatory, immune,
and apoptotic responses [1-3]. NF-κB is ubiquitously
present in the cytoplasm and its activity is normally
suppressed by association with inhibitor IκB [4]. The
intracellular NF-κB signaling cascade is initiated by a
variety of inducers including proinflammatory cytokines
TNF-α, IL-1 or endotoxins [5,6]. The aberrant activity
to the NF-κB signaling pathway has been implicated in
the development of a number of human diseases includ-
ing cancer, auto-immune and chronic inflammatory
conditions [3,7,8]. Therefore, inhibitors of the NF-κB
signaling pathway could offer potential therapeutic
value for the treatment of such diseases [9,10].* Correspondence: duncanleung@umac.mo; edmondma@hkbu.edu.hk
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reproduction in any medium, provided the orThe IκB kinase is a multi-component complex composed
of two catalytic subunits, IKKα and IKKβ and a regulatory
unit NF-κB essential modulator (NEMO) [11-13]. Although
both catalytic units are able to phosphorylate IκB, IKKβ has
been shown to play the dominant role in activating NF-κB
signaling in response to inflammatory stimuli [14,15]. Phos-
phorylated IκB is subsequently tagged by the E1 ubiquitin
enzyme and degraded by the proteasome to liberate active
NF-κB. Free NF-κB then translocates into the nucleus, where
it binds to its cognate DNA site and enhances the expression
of a number of genes related to the immune response, cell
proliferation and survival [16,17]. Consequently, IKKβ repre-
sents an attractive target in the NF-κB pathway for the deve-
lopment of anti-inflammatory or anti-cancer therapeutics.
Virtual screening (VS) has emerged as a powerful tool in
drug discovery complementing the vast array of popular
but relatively costly high-throughput screening technologies
[18,19]. Using virtual screening, the number of compounds
to be evaluated in vitro could be dramatically decreased,
which could greatly reduce the time and resource costs of
drug discovery efforts. Meanwhile, natural products (NPs)
have long provided a valuable source of inspiration toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scaffolds, favourable biocompatibility and evolutionarily
validated bioactive substructures [20,21]. Combining these
two ideas, our group has previously identified natural prod-
uct or small molecule inhibitors antagonizing cancer or
inflammation-related targets using virtual screening
[22-28]. For example, we have successfully identified
natural product or natural product-like compounds
targeting the c-myc oncogene G-quadruplex, tumor
necrosis factor-alpha (TNF-α) and NEDD8-activating
enzyme (NAE) [29-34].
In recent years, many small molecule inhibitors of
IKKβ have been identified using pharmacophore-based
or high-throughput screening approaches [32-39]. How-
ever, the recent publication of the IKKβ X-ray crystal
structure with its inhibitor [40] enables the use of
powerful structure-based in silico methods for the dis-
covery of novel IKKβ inhibitors. We thus set out to
identify interesting molecular scaffolds for the develop-
ment of future IKKβ inhibitors from a large natural
product library using high-throughput structure-based
virtual screening. The X-ray co-crystal structure of the
IKKβ with the reference inhibitor ((4-{[4-4-chlorophenyl)
pyrimidin-2-yl]amino}phenyl[4-(2-hydroxyethyl)piperazin-
1-yl]methanone (PDB: 3RZF) was used for our molecular
modeling investigations (Figure 1) [40]. To our knowledge,
this work is the first example of an IKKβ inhibitor identi-
fied using high-throughput molecular docking of a natu-




The workflow of this virtual screening (VS) campaign is
outlined in Scheme 1. The molecular model of IKKβ for
VS was built using the recently reported X-ray co-crystal
structure of IKKβ with its inhibitor. The binding site
of IKKβ was defined to be within 3Å of the boundFigure 1 Chemical structures of the small molecule IKKβ inhibitors.
Chemical structures of IKKβ inhibitors (4-{[4-(4-chlorophenyl)phyrimidin2-
yl]amino}phenyl[4-(2-hydroxyethyl)piperazin-1-yl]methanone (reference
compound) (left) and NP-derived benzoic acid derivative
(1) (right).inhibitor, which is situated at the hinge loop connecting
the N and C lobes of the IKKβ KD domain. Over 90,000
structures from a chemical library of natural products and
natural product-like compounds were screened in silico
against the binding pocket of IKKβ [31]. The flexible
ligands were docked to a grid representation of the recep-
tor and assigned a score reflecting the quality of the
complex according to the Internal Coordinate Mechanics
(ICM) method [ICM-Pro 3.6-1d molecular docking soft-
ware (Molsoft)]. Compounds with ICM docking scores of
under -30 kcal/mol were shortlisted. Based on visual in-
spection and availability from the commercial sources, 12
compounds containing distinctive chemical scaffolds were
chosen (Additional file 1: Figure S1). These compounds
were purchased and were subjected to a preliminary luci-
ferase assay (Additional file 1: Figure S2). The results
showed that 4 out of the 12 compounds were able to in-
hibit NF-κB transcription activity by 20% or more com-
pared to the untreated control at a concentration of 20
μM. The benzoic acid derivative (1) (Figure 1) inhibited
NF-κB activity by over 40% relative to the untreated con-
trol, while compounds 3, 9 and 10 exhibited weaker inhibi-
tory activities of 20–30%. Compounds containing the
benzoic acid moiety are known to display a variety of
pharmacological effects and a number of benzoic acid deri-
vatives possessing anti-inflammatory properties have been
isolated from natural sources. For example, (E)-3-acetyl-6-
(3,7-dimethylocta-2,6-dienyloxy)-2,4-dihydroxybenzoic acid
isolated from M. semecarpifolia has been reported to sup-
press fmet-Leu-Phe (fMLP)-induced superoxide anion
generation and elastase release by human neutrophils
(Additional file 1: Table S1) [41]. In addition, the nat-
ural benzenoid antrocamphin A extracted from the
fruiting body of A. camphorata was found to down-
regulate iNOS and COX-2 expression at both transcrip-
tional and translational levels via suppression of NF-κB
nuclear translocation [42]. A synthetic benzoic acid-
derived compound GS143 reported by Furuichi, Shimbara
and co-workers blocked NF-κB translocation through
inhibition of IκBα ubiquitination and subsequent IκBα
degradation [43]. To our knowledge, no biological activ-
ity of 1 has been reported in the literature. The identifi-
cation of this natural product-derived benzoic acid
scaffold as an IKKβ inhibitor could contribute to an
understanding of the molecular mechanisms of the anti-
inflammatory properties of this class of compounds.
Furthermore, we envisage that this natural product de-
rivative could serve as a valuable scaffold for the devel-
opment of future IKKβ inhibitors.
Molecular modeling analysis
The ATP binding site of kinases generally consists of a
narrow and hydrophobic region located between the
N-lobe and C-lobe of the kinase domain (KD), with the
Scheme 1 Schematic diagram showing the workflow of this high-throughput molecular docking campaign.
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hydrogen bond donor and acceptor residues from the
protein backbone [44]. The most important receptor
residue in determining kinase inhibitor specificity is the
“gatekeeper” residue, which controls the access of the
inhibitor to the hydrophobic pocket. In the crystal struc-
ture of IKKβ, the gatekeeper residue is Met96, while
Glu97, Tyr98 and Cys99 form the hinge region of the KD
of IKKβ. The backbone groups of Glu97 and Cys99 are
able to provide hydrogen bonding interactions with the
inhibitor. In addition, the ATP binding site of IKKβ is
partly covered by an activation loop comprised of
serine, threonine and tyrosine residues in the unpho-
sphorylated state. In particular, the N-terminal side of
the activation loop contains the Asp166, Leu167 and
Gly168 DLG triad which is involved in catalytic transfer
of the γ-phosphate group in most kinase ATP binding
sites (Figure 2a) [40].
Our molecular docking analysis revealed that the top-
scoring binding mode of the natural product derivative 1
to the IKKβ complex is similar to that of the reference
compound. The bound inhibitor in the co-crystal struc-
ture of IKKβ interacts with the ATP binding pocket in
shape-driven manner [40]. While the structure of the
reference compound contains the anilinopyrimidine
motif that is found in other kinase inhibitors such as
imatinib [45], no detectable hydrogen bonds between
the hinge region of IKKβ and the anilinopyrimidinemoiety of the reference compound were recorded. The
aromatic rings of the reference compound span the
hinge loop while its terminal chlorine atom points to-
wards the gatekeeper residue Met96 (Figure 2b).
By comparison, the benzoic acid moiety of 1 is situ-
ated at the end of the hinge loop with predicted hydro-
gen bonding interactions between the carboxyl oxygen
and amide oxygen atoms of 1 with the phenolic hydro-
gen atom of Tyr98 and the backbone amino group of
Gly102, respectively (Figure 2c). The pendant side chain
of 1 is predicted to be situated in a hydrophobic binding
pocket also occupied by the reference compound. We
envisage that 1 could act as a reversible inhibitor of
IKKβ by blocking the nucleotide recognition domain
that binds ATP [40]. The binding score for 1 with the
IKKβ complex was calculated to be -35.28 kcal/mol,
reflecting a strong interaction between the compound
and the IKKβ binding site.
The other eleven compounds were also predicted to
situate in the hinge region of the binding pockets in
the docking analysis. Most of the compounds could
form hydrogen bonds with the hinge residues including
Glu97, Cys99 and Glu100. Furthermore, several of the
compounds formed additional hydrogen bonds with
the residues in the solvent accessible region (Arg31
and Lys106). The lowest energy binding pose of the




Figure 2 Molecular docking analysis of reference compound and 1 to the IKKβ protein complex. a) The KD domain of IKKβ is
displayed in the ribbon form. The activation loop, gatekeeper residue (Met 96), hinge region (Glu97-Cys99) are visualized. Low-energy
binding conformations of b) 1 and c) reference compound to IKKβ protein complex were generated by virtual ligand docking. Small
molecules inhibitor 1 and reference compound is depicted as a ball-and-stick model showing carbon (yellow), hydrogen (grey), oxygen
(red) and nitrogen (blue) atoms. H-bonds are indicated as dotted lines. The binding pocket of the IKKβ is represented as a translucent
green surface.
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IKKβ over four other kinases (PKCα, PAK4, CaMK2α
and JAK2) using molecular modeling. While compound
1 was predicted to bind at the ATP binding sites of the
four other kinases, the ICM docking energies of the
1-kinase complexes were significantly less negative than
that for IKKβ (Additional file 1: Table S3). Molecules
exhibiting such weak binding energies would be
expected to be inactive in vitro.
1 inhibits IκBα phosphorylation in vitro
Encouraged by the molecular docking results and the
preliminary luciferase screening experiment, we investi-
gated the effect of compound 1 on IKKβ phosphorylation
activity. Inhibition of IKKβ phosphorylation activity would
be expected to lead to a decrease in GST-IκBα substrate
phosphorylation level. Encouragingly, a dose-dependent
reduction in IKKβ activity was observed upon the incuba-
tion with 1, with an estimated IC50 value of ca. 50 μM
(Figure 3).
1 inhibits TNF-α induced NF-κB signaling in a HepG2
cell line
We sought to investigate the ability of compound 1 to
inhibit NF-κB signaling in human cells using a luciferase
assay. A stably-transfected HepG2 cell line carrying the
luciferase reporter gene driven by a promoter containing
multiple copies of the NF-κB response element was used
in this study. The transcriptional activity of NF-κB wasFigure 3 Inhibition of IKKβ phosphorylation activity. Microtiter
plates with GST-IκBα were incubated with IKKβ together with 1 at
the indicated concentrations. GST-IκBα phosphorylated level was
detected using an anti-phospho IκBα (Ser32/Ser36) antibody and
horseradish peroxidase conjugated secondary antibody.
Approximate IC50 value of 1 = 50 μM. Error bars represent the
standard deviations of the results from three independent
experiments.determined by measuring the luciferase activity of the
cell lysates using a luminometer. We performed a dose
response analysis of compound 1 and three other hit
compounds in attenuating TNF-α-induced NF-κB sig-
naling (Figure 4). Compound 1 inhibited TNF-α-induced
luciferase activity in a dose-dependent manner with an
estimated IC50 value of ca. 10 μM. While the three other
compounds also inhibited TNF-α-induced luciferase ac-
tivity, their inhibition potencies were around 10-fold
lower compared to compound 1.
Based on the results of the IKKβ assay and the mo-
lecular modeling analysis, we envisage that the inhibition
of TNF-α-induced NF-κB signaling by 1 could be attrib-
uted, at least in part, to the inhibition of IKKβ activity
in vitro, thus preventing the degradation of the NF-κB
repressor IκBα. The slightly higher potency of 1 in the
cell-based luciferase assay compared to the enzyme assay
is possibly due to a multi-target effect of 1, suggesting
that this compound could potentially influence other
steps involved in NF-κB activation.
Conclusions
In conclusion, we have discovered a new small molecule
IKKβ inhibitor from a large natural product library of
90,000 compounds using high-throughput structure-
based molecular docking. The benzoic acid derivative 1
is able to inhibit IKKβ activity in both cell-free and sys-
tem with micromolar potency. Furthermore, compound
1 could inhibit IKKβ-mediated NF-κB signaling pathway
in human cancer cells. We envisage that compound 1
attenuates the in cellulo transcriptional activity of NF-
κB, at least in part, by abrogating the activity of IKKβ.
The discovery of this natural product-like derivative pro-
vides medicinal chemists with a structurally interesting
scaffold, facilitating further chemical modifications in
order to sample greater regions of the chemical space of
potential IKKβ inhibitors. We are currently investigating
the effects of 1 on the proteins involved in NF-κB signal-
ing and conducting in silico lead optimization to gener-
ate more potent analogues of 1 for in vitro biological
testing.
Methods
Materials and cell lines
The NP/NP-like compound collection, which includes
compound 1 and the other tested compounds, was
obtained from InterBioScreen (Moscow, RUS). The K-
LISA™ IKKβ Inhibitor Screening Kit was obtained from
Calbiochem (Darmstadt, Germany). Passive lysis buffer
and luciferase assay reagent were obtained from Pro-
mega Corporation (Madison, WI, USA). HepG2 and
HepG2-NF-κB-Luc cells were provided by Prof. Y.C.
Cheng (Department of Pharmacology, Yale University
School of Medicine, USA). Cells cultured in Minimum
Figure 4 Inhibition of cellular IKKβ mediated NF-κB activity. HepG2 cells stably transfected with the NF-κB–luciferase gene were stimulated
with TNF-α pre-incubated with the indicated concentrations of 1 and other three hit compounds (compounds 3, 9 and 10). Cell lysates were
analyzed for luciferase activity to determine the extent of NF-κB inhibition. Error bars represent the standard deviations of the results from three
independent experiments.
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incubated at 37°C/5% CO2 and passaged three times a
week.
IKKβ enzymatic activity
IKKβ activity was determined using the ELISA-based
(K-LISA™) IKKβ Inhibitor Screening Kit according
to the manufacturer’s instructions. The GST-IκBα
50-amino acid peptide that includes the Ser32 and
Ser36 IKKβ phosphorylation sites was used as a sub-
strate and was incubated for 30 min at 30°C with human
recombinant IKKβ in the presence of DMSO vehicle or
different concentrations of 1 in a glutathione-coated
96-well plate. The phosphorylated GST-IκBα substrate
was subsequently detected using anti-phospho-IκBα
(Ser32/Ser36) antibody and a horseradish peroxidase-
conjugated secondary antibody. The samples werefinally incubated with TMB solution, and the color de-
velopment was monitored at 450 nm on a plate reader
(Bio-Rad).
NF-κB transactivation activity
Exponentially growing HepG2-NF-κB-Luc cells were
seeded overnight at 1 × 104 cells/well in a 48-well plate.
On the next day, the cells were pre-incubated with the
indicated concentrations of 1 for 1 h before stimulation
by 5 ng/mL of TNF-α for an additional 3 h. Passive lysis
buffer (50 μL) was added to each well and the plate was
incubated for 15 min with shaking. A 20 μL aliquot from
each well was mixed with 70 μL luciferase assay reagent
in a 96-well white plate. The transcriptional activity was
determined by measuring the activity of firefly luciferase
in a multi-well plate luminometer (Fusion α-FP, Perkin-
Elmer).
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A natural product or natural product-like chemical li-
brary containing over 90,000 compounds was screened
in silico. Molecular docking was performed by using the
ICM-Pro 3.6-1d program (Molsoft). According to the
ICM method, the molecular system was described by
using internal coordinates as variables. Energy calcula-
tions were based on the ECEPP/3 force field with a
distance-dependent dielectric constant. The biased prob-
ability Monte Carlo (BPMC) minimization procedure
was used for global energy optimization. The BPMC
global-energy-optimization method consists of 1) a ran-
dom conformation change of the free variables accord-
ing to a predefined continuous probability distribution;
2) local-energy minimization of analytical differentiable
terms; 3) calculation of the complete energy including
nondifferentiable terms such as entropy and solvation
energy; 4) acceptance or rejection of the total energy
based on the Metropolis criterion and return to step (1).
The binding between the small molecules and NAE-
NEDD8 were evaluated with a full-atom ICM ligand
binding score from a multireceptor screening bench-
mark as a compromise between approximated Gibbs free
energy of binding and numerical errors. The score was
calculated by:
Sbind ¼ Eint þ TΔSTor þ Evw þ α1Eel þ α2Ehb þ α3Ehp
þ α4Esf
where Evw, Eel, Ehb, Ehp, and Esf are Van der Waals, elec-
trostatic, hydrogen bonding, and nonpolar and polar
atom solvation energy differences between bound and
unbound states, respectively. Eint is the ligand internal
strain, ΔSTor is its conformational entropy loss upon
binding, and T = 300 K, and αi are ligand- and receptor
independent constants. The initial model of IKKβ was
built from the X-ray crystal structure of the Inhibitor of
kappaB kinase beta (PDB: 3RZF) according to a previ-
ously reported procedure. Hydrogen and missing heavy
atoms were added to the receptor structure followed by
local minimization by using the conjugate gradient algo-
rithm and analytical derivatives in the internal coordi-
nates. In the docking analysis, the binding site was
assigned across the entire structure of the protein com-
plex. Each compound was assigned the MMFF force
field atom types and charges and was then subjected to
Cartesian minimization. The ICM docking was per-
formed to find the most favorable orientation. The
resulting trajectories of the complex between the small
molecules and protein complex were energy minimized,
and the interaction energies were computed. Each com-
pound was docked three times and the minimum of the
three scores was used. The 12 highest scoring com-
pounds were utilized for biological testing withoutfurther selection. The crystal structures of PAK4 (4APP),
PKCα (3IW4), CAMK2α (2VZ6) and JAK2 (3IOK) were
also prepared and compound 1 was docked to these mo-
lecular models individually using the aforementioned
procedures.
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Additional file 1: Figure S1. Chemical structures of the 11 other high-
scoring compounds selected for preliminary biological evaluation. Figure
S2. Preliminary experimental screening of the 12 compounds on
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NF-κB signaling pathway. Table S2. Lowest-energy binding pose of the
11 other compounds with the ATP binding site in the KD domain of
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